ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Session » Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

Abstract Number: 1801
The Effect of Ixekizumab versus Adalimumab on Individual Components of the ACR Composite Score, with and Without Concomitant Methotrexate or Other Conventional Synthetic DMARDs at 52 Weeks in Patients with Psoriatic Arthritis
Abstract Number: 1802
Comparison of Axial and Peripheral Manifestations in Patients with Psoriatic Arthritis and Ankylosing Spondylitis in Upadacitinib Clinical Trials
Abstract Number: 1803
Long-term Safety of Guselkumab (TREMFYA®) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years
Abstract Number: 1804
Targeted Safety Analyses of Guselkumab (TREMFYA®): Long-term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis
Abstract Number: 1805
Low Rates of Radiographic Progression with 2 Years of Guselkumab (TREMFYA®), a Selective Inhibitor of the Interleukin-23p19 Subunit: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study of Biologic-naïve Patients with Active Psoriatic Arthritis
Abstract Number: 1806
Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA®/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition
Abstract Number: 1807
Relationships Between Fatigue and Hemoglobin/C-Reactive Protein Levels and Associations Between Fatigue and Clinical Response in Patients with Active Psoriatic Arthritis: Results from Two Randomized Controlled Trials of Guselkumab (TREMFYA®)
Abstract Number: 1808
Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial
Abstract Number: 1809
Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis
Abstract Number: 1810
Current Medication Practices and Preferences Among Patients with Psoriatic Arthritis (PsA)
Abstract Number: 1811
Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-controlled Studies
Abstract Number: 1812
Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 DISCOVER Program
Abstract Number: 1813
Clinical Characteristics & Outcomes Associate with Work Productivity in Bio-naïve Patients with Active Psoriatic Arthritis Through Week 24 of the DISCOVER-2 Study
Abstract Number: 1814
Patient Characteristics and Clinical Features Associate with Health-Related Quality of Life in Bio-naïve Patients with Active Psoriatic Arthritis Through Week 24 of the DISCOVER-2 Study
Abstract Number: 1815
Randomised, Double-blind, Placebo-controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
Abstract Number: 1816
Treatment of Non-biologic-DMARD-IR PsA Patients with Upadacitinib or Adalimumab Results in the Modulation of Distinct Functional Pathways: Proteomics Analysis of a Phase 3 Study
Abstract Number: 1817
Comparison of Composite Indices for Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib: A Post-Hoc Analysis from SELECT-PsA 1
Abstract Number: 1818
Real-World Efficacy of TNF Inhibitors for Treatment of Psoriatic Arthritis by Disease Domains: 6-Month Findings from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Number: 1819
Tildrakizumab Efficacy and Safety in Patients with Psoriatic Arthritis by Metabolic Syndrome Status
Abstract Number: 1820
Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active PsA in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Abstract Number: 1821
Role of Patient Organizations in Implementation of Recommended Non-pharmacological Treatment Modalities in Spondyloarthritis: Evidence for the Effectiveness of Self-management Strategies
Abstract Number: 1822
Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Abstract Number: 1823
Efficacy of Upadacitinib in Patients with Active Psoriatic Arthritis and a Low or High Swollen Joint Count: A Subgroup Analysis of 2 Phase 3 Studies
Abstract Number: 1824
Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study
Abstract Number: 1825
Secukinumab Provides Clinical Improvements in Patients with Active Oligoarticular Psoriatic Arthritis: Results from a Pooled Analysis of 5 Phase 3 Studies
Abstract Number: 1826
Reduced Burden on Paid and Household Work Productivity with Stringent Thresholds of Disease Control: Further Results from Long-Term Certolizumab Pegol Treatment in Patients with Psoriatic Arthritis
Abstract Number: 1827
Psoriatic Arthritis, Female Sex and Increased Baseline Skin Severity Are Associated with Drug Persistence in Ustekinumab-Treated Patients with Psoriasis in the BADBIR Cohort
Abstract Number: 1828
Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis up to 3 Years: An Updated Integrated Safety Analysis
Abstract Number: 1829
Pharmacological Treatment of Enthesitis – A Systematic Review on the Efficacy of the Available Options
Abstract Number: 1830
Discontinuation of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis and Psoriasis
Abstract Number: 1831
Predictors of Response, Adverse Events and Treatment Retention in Psoriatic Arthritis Patients Treated with Golimumab in a Prospective, Observational Registry
Abstract Number: 1832
Secukinumab Therapy in Biologic-naïve vs. Biologic-experienced Patients: Real-world Effectiveness, Persistence and Safety Results from the Rheumatic Diseases Portuguese Registry
Abstract Number: 1833
Risk of Major Adverse Cardiovascular Events (MACE) with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
Abstract Number: 1834
To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population
Abstract Number: 1835
Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences